No abstract available
Keywords:
HCC; biomarkers; hepatocellular carcinoma; immunotherapy; tumor prognosis.
Grants and funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The University of Padova, Department of Medicine-DIMED has provided funds for scientific research on HCC studies with the DOR project number 2023-2327032 to the P.I. LC.